## HISTORICALLY ACCEPTED USE

## **Tertiary and Quaternary Committee**

# **Executive Summary**

Date: March 2019

Medicine (INN): Calcium folinate

Medicine (ATC): V03AF03

Indication/s (ICD10 code): 1. Potentiating agent with 5-Fluorouracil (5-FU); 2. Rescue following high dose

methotrexate.

Patient population/s: Various malignancies

Prevalence of condition: Varied
Level of Care: Tertiary and Quaternary

Prescriber Level: Oncologist and haemotologist (adult and paediatrics)

Current standard of Care: Calcium folinate together with 5-FU and other agents

Efficacy estimates: Calcium folinate shown to modulate 5-FU in patients with advanced adenocarcinoma of the

colon. <sup>1</sup> Tetrahydrofolate rescue in patients receiving high dose dihydrofolate reductase inhibition.

## **Historically accepted use Criteria**

Criteria		Comment			
1	The medicine is included in the WHO Model Essential		YES	NO	
	Medicines List, either as a core or complementary		Х		
	item, for the indication requested.				<b>-</b>
2	The medicine is currently registered by SAHPRA for the		YES	NO	
	indication.		Х		
					_
3	There is evidence of long-established (prior to 1996*)		YES	NO	
	safe and effective use of the medicine for the		Х		7
	recognised indication in the public health sector.	Comn			_
4	There are no new safety or efficacy concerns.		YES	NO	
			Х		
		Comn	nent:		_
5	The budget impact is not expected to be sufficiently		YES	NO	
	large that a de novo review is justified.		Х		
		Comment:			
6	There is equitable access across the country, and is		YES	NO	
	limited only by the availability of adequately trained		Х		7
	staff and availability of equipment.	Comn	nent	I	_

<sup>\*</sup> The Essential Drugs Programme (EDP) of South Africa was established in terms of the National Drug Policy (NDP) which was implemented in 1996

#### Recommendation

It is recommended that calcium folinate be included as an Essential Medicine for various malignancies.

<sup>1</sup> Rustum YM. Biochemical rationale for the 5-fluorouracil leucovorin combination and update of clinical experience. Journal of Chemotherapy. 1990 2(1):5-11.